Cocrystal Pharma. has been granted a patent for compounds that inhibit influenza virus replication and reduce viral load. The patent includes a specific compound structure, referred to as Formula (I), along with its pharmaceutically acceptable salts. GlobalData’s report on Cocrystal Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cocrystal Pharma, was a key innovation area identified from patents. Cocrystal Pharma's grant share as of June 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12037333B2 outlines a novel compound characterized by a specific chemical structure, referred to as Formula (I), along with its pharmaceutically acceptable salts. The claims detail various structural modifications and substitutions of the compound, including specific groups (R1, R2, R3, etc.) that can be hydrogen, hydroxyl, or other functional groups. Notably, the compound is designed to inhibit the endonuclease activity of the influenza polymerase PA, targeting both Influenza A and B viruses. The patent also describes pharmaceutical formulations that incorporate this compound alongside acceptable excipients, enhancing its potential for therapeutic applications.
In addition to the compound's structural claims, the patent delineates methods for treating or preventing influenza infections in hosts by administering the compound in therapeutic amounts. These methods aim to reduce viral replication and endonuclease activity, thereby mitigating the effects of the virus. Furthermore, the patent allows for the combination of the compound with other antiviral agents, such as pyrazinecarboxamide compounds or neuraminidase inhibitors, to potentially enhance efficacy against influenza viruses. Overall, the patent presents a comprehensive approach to developing antiviral therapies targeting influenza through a specific chemical entity and its derivatives.
To know more about GlobalData’s detailed insights on Cocrystal Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
